Strides Pharma Science · NSE: STAR · BSE: 532531

Q4 FY21 results · Jan–Mar 2021

Strides Pharma Science reported revenue from operations of ₹908.49 crore (up 46.9% from Q4 FY20) and net profit of ₹43.74 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY21	Q4 FY20	YoY	Q3 FY21	QoQ
Revenue from operations	908.49	618.64	+46.9%	832.02	+9.2%
Other income	13.05	17.65	−26.1%	13.20	−1.2%
Total income	921.54	636.29	+44.8%	845.23	+9.0%
Profit before share of associates & JVs and tax	75.89	(173.08)	Turned profit	72.85	+4.2%
Share of profit/(loss) of associates & JVs	(19.82)	(44.78)		(26.91)
Net profit for the period	43.74	(206.57)	Turned profit	35.16	+24.4%
Attributable to shareholders of the company	46.09	(203.93)	Turned profit	37.85	+21.8%
EPS, basic (₹)	5.14	(22.77)	Turned profit	4.22	+21.8%
Net margin (%)	4.8	-33.4		4.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY21	Q4 FY20	YoY	Q3 FY21	QoQ
Revenue from operations	633.60	441.74	+43.4%	421.08	+50.5%
Other income	23.31	27.26	−14.5%	16.23	+43.6%
Total income	656.90	469.00	+40.1%	437.31	+50.2%
Profit before tax	68.69	47.77	+43.8%	27.36	+151.0%
Net profit for the period	48.08	26.37	+82.3%	20.49	+134.6%
EPS, basic (₹)	5.36	2.94	+82.3%	2.29	+134.1%
Net margin (%)	7.6	6.0		4.9

Consolidated

Filed with BSE: 27 May 2021, 18:05 IST
Board meeting: 27 May 2021
Period: 01 Jan 2021 to 31 Mar 2021
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 27 May 2021, 18:05 IST
Board meeting: 27 May 2021
Period: 01 Jan 2021 to 31 Mar 2021
Review status: Audited
Source: XBRL filing on BSE